final action
on 11 Sep 2024
Last Applicant/ Owned by
85748 Garching
DE
Serial Number
79397582 filed on 08th Feb 2024
Registration Number
N/A
Correspondent Address
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
Scientific and technological services and research relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters, in particular medical and pharmacological research services relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters. Medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, in particular for the prod Read More
Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and radionuclide therapy, peptide receptor radionuclide therapy (PRRT), personal nuclear medicine and precision oncology; medical services for theranostics in the field of precision oncology.
N/A
N/A
Scientific and technological services and research relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters, in particular medical and pharmacological research services relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters.
N/A
N/A
Medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, in particular for the production of actinium-225 and/or bismuth-213 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of actinium-225 and/or bismuth-213 in GMP quality; radionuclide generator for radiopharmaceutical purpose.
N/A
N/A
Radiopharmaceutical diagnostic and/or therapeutic preparations for medical and/or pharmaceutical purposes, in particular radiopharmaceutical preparations for endoradionuclide therapy, brachytherapy, positron emission tomography (PET), single photon emission computed tomography (SPECT), target radionuclide therapy and peptide receptor radionuclide therapy (PRRT); radiopharmaceutical products, in particular actinium-containing and/or bismuth-containing radiopharmaceutical products in GMP [Good Manufacturing Practice] quality; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular actinium-225 and/or bismuth-213; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular actinium-225 and/or bismuth-213 for the treatment of tumour diseases; target radiopharmaceuticals containing a target molecule, in particular a peptide or an antibody, depending on the indication, and a medical radioactive isotope; radiopharmaceuticals containing actinium-225 and/or bismuth-213 and its complexes.
N/A
N/A
Chemical substances, chemical materials and chemical preparations for use in the manufacture of medical and/or radiopharmaceutical products; chemical raw materials, in particular actinium-225 radiochemical and/or bismuth-213, for the formulation of radiopharmaceutical products.
N/A
N/A
No 79397582
No Service Mark
No
No
No
No
No
Yes
Yes
No
No
24.17.12 -
Infinity symbol
26.01.21 -
Circles that are totally or partially shaded
26.01.31 -
Five or more circles
Status Date | Action Taken |
---|---|
30th Sep 2024 | REFUSAL PROCESSED BY IB |
11th Sep 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
11th Sep 2024 | REFUSAL PROCESSED BY MPU |
09th Sep 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
08th Sep 2024 | NON-FINAL ACTION WRITTEN |
02th Sep 2024 | ASSIGNED TO EXAMINER |
20th Jun 2024 | APPLICATION FILING RECEIPT MAILED |
20th Jun 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
13th Jun 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |